News

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...
Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving ...